These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 400529

  • 21. Hemosiderosis in a patient on regular hemodialysis: treatment by desferrioxamine.
    Baker LR, Barnett MD, Brozovic B, Cattell WR, Ackrill P, McAlister J, Nimmon C.
    Clin Nephrol; 1976 Jul; 6(1):326-8. PubMed ID: 954239
    [Abstract] [Full Text] [Related]

  • 22. [Specific treatment of excessive iron deposition in the tissues].
    Plachecka-Gutowska M, Mikolajew M.
    Pol Arch Med Wewn; 1965 Jul; 35(1):111-7. PubMed ID: 5900073
    [No Abstract] [Full Text] [Related]

  • 23. Desferrioxamine-chelatable iron (DCI), a component of serum non-transferrin-bound iron (NTBI) used for assessing iron chelation therapy.
    Breuer W, Ermers MJ, Pootrakul P, Abramov A, Hershko C, Cabantchik ZI.
    Transfus Sci; 2000 Dec; 23(3):241-2. PubMed ID: 11099901
    [No Abstract] [Full Text] [Related]

  • 24. [Comparative evaluation of two models of hemosiderosis for analysis of iron chelators].
    Minina LT, Prostakova TM, Meshchano AIu, Kol'tsova GN, Bovenko VN.
    Biull Eksp Biol Med; 1996 Sep; 122(9):359-60. PubMed ID: 8974501
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. [Therapy of hemosiderosis with deferoxamine].
    Strohmeyer G, Stremmel W.
    Dtsch Med Wochenschr; 1984 Nov 02; 109(44):1669-70. PubMed ID: 6489179
    [No Abstract] [Full Text] [Related]

  • 27. [Diseases caused by iron metabolism disorders and their therapy].
    Stacher A.
    Wien Z Inn Med; 1969 Nov 02; 50(3):89-105. PubMed ID: 4903041
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. [Iron metabolism].
    Maspes VE, Barretto OC, Tamigaki M.
    Rev Hosp Clin Fac Med Sao Paulo; 1987 Nov 02; 42(6):282-9. PubMed ID: 3455558
    [No Abstract] [Full Text] [Related]

  • 30. [Myocardiopathy caused by iron deposition. Treatment with chelating agents].
    Rodríguez Reguero JJ, Iglesias Cubero G, Espolita Santos A, López de la Iglesia JM, Enríquez Martín J, Tomás Mauri J, López-Negrete L.
    Rev Esp Cardiol; 1985 Nov 02; 38(5):356-7. PubMed ID: 4081244
    [No Abstract] [Full Text] [Related]

  • 31. [Desferrioxamine in patients with hemochromatosis and hemosiderosis].
    Maspes V, Tamigaki M, Gomes ZJ, Jamra M.
    Rev Hosp Clin Fac Med Sao Paulo; 1966 Nov 02; 21(4):181-95. PubMed ID: 5918167
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. [Effect of desferrioxamine B and 2-(beta-aminoethoxy)cyclohexylaminetetraacetate in experimental hemochromatosis in rats and in primary hemochromatosis of man].
    Bohne F, Lessmann J.
    Arzneimittelforschung; 1969 Jun 02; 19(6):944-7. PubMed ID: 5820039
    [No Abstract] [Full Text] [Related]

  • 34. Iron-chelating therapy.
    Hershko C, Weatherall DJ.
    Crit Rev Clin Lab Sci; 1988 Jun 02; 26(4):303-45. PubMed ID: 3077034
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. [The treatment of post-transfusional hemochromatosis with chelating agents].
    Delvaux D, Andrien JM, Fillet G.
    Rev Med Liege; 1981 Jun 01; 36(11):477-80. PubMed ID: 6789438
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Iron metabolism in thalassemia intermedia.
    Fiorelli G, Fargion S, Piperno A, Battafarano N, Cappellini MD.
    Haematologica; 1990 Jun 01; 75 Suppl 5():89-95. PubMed ID: 2086386
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.